文献速递重症综合管理与镇静镇痛心脑血管急症

天麻素预防心脏手术后谵妄的疗效与安全性:一项随机安慰剂对照临床试验

Efficacy and safety of gastrodin in preventing postoperative delirium following cardiac surgery: a randomized placebo controlled clinical trial.
PubMed 文献 · Crit Care · 2025-03-11
一句话结论心脏搭桥术后天麻素静脉输注600 mg每日两次可降低术后谵妄发生率(19.5% vs 35.9%,RR 0.54),并提高出院可能,但需更大样本研究确认。

该双盲随机安慰剂对照试验纳入160例18-75岁拟行冠状动脉旁路移植术(伴或不伴瓣膜置换)患者,1:1随机接受天麻素600 mg每日两次静脉输注或安慰剂,自手术日至术后第6天。改良意向治疗分析155例(天麻素77例、安慰剂78例),术后谵妄发生率天麻素组19.5% vs 安慰剂组35.9%(RR 0.54,95%CI 0.32-0.93,p=0.022),出院可能天麻素组更高(subhazard ratio 1.20,95%CI 1.00-1.84,p=0.049),不良事件两组分别为9.1%(7/77)和14.1%(11/78),均与药物无关。作者认为天麻素显著减少术后谵妄并改善出院结局,但需更大研究确认其预防谵妄的疗效。

要点

  • 心脏搭桥术后天麻素组谵妄发生率19.5%,安慰剂组35.9%,相对风险0.54(95%CI 0.32-0.93,p=0.022)。
  • 天麻素组出院可能更高(subhazard ratio 1.20,95%CI 1.00-1.84,p=0.049)。
  • 院内POCD发生率安慰剂组2.9%、天麻素组4.0%。
  • 不良事件天麻素组9.1%(7/77) vs 安慰剂组14.1%(11/78),无药物相关不良事件。
  • 作者认为天麻素可减少术后谵妄并改善出院结局,但需更大样本研究确认预防谵妄的疗效。

适用人群与场景

  • 年龄18-75岁、拟行冠状动脉旁路移植术(伴或不伴瓣膜置换)的心脏手术患者。

处置流程与药物剂量

  • 天麻素组:自手术日至术后第6天,天麻素600 mg每日两次静脉输注。
  • 安慰剂组:同时间点给予安慰剂静脉输注。

研究设计与关键结果

  • 研究类型:双盲、随机、安慰剂对照临床试验;随机160例,改良意向治疗分析155例(天麻素77例、安慰剂78例)。
  • 共同主要终点:术后谵妄发生率天麻素组19.5% vs 安慰剂组35.9%,相对风险0.54(95%CI 0.32-0.93,p=0.022),自ICU入科至术后第7天评估。
  • 共同主要终点:院内POCD发生率安慰剂组2.9%、天麻素组4.0%;术后1个月和3个月评估。
  • 关键次要终点:出院可能天麻素组更高(subhazard ratio 1.20,95%CI 1.00-1.84,p=0.049)。
  • 不良事件:天麻素组9.1%(7/77) vs 安慰剂组14.1%(11/78),均与药物无关。

证据类型、等级与局限

  • 证据类型:随机安慰剂对照临床试验(双盲)。
  • 试验注册:中国临床试验注册中心(ChiCTR1800020414)。
  • 局限:作者指出需要更大规模的研究来确认其预防谵妄的疗效。

对床旁实践的改变

  • 作者认为,天麻素静脉输注可显著减少冠状动脉旁路移植术患者的术后谵妄并改善出院结局,但需更大规模研究确认其预防谵妄的疗效。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Delirium and postoperative cognitive dysfunction (POCD) are common complications post-cardiac surgery, yet no specific medical intervention is currently recommended for prevention. This study aimed to evaluate the efficacy of gastrodin infusion in preventing delirium and POCD in critically ill patients following cardiac surgery.

MATERIAL AND METHODS: A double-blind, randomized, placebo-controlled trial was conducted on patients aged 18-75, scheduled for coronary artery bypass grafting (CABG) surgery, with or without valve replacement. Participants were randomized in a 1:1 ratio to receive gastrodin infusion 600 mg twice daily or placebo from the day of surgery until the postoperative day (POD) 6. The co-primary outcomes were the incidences of delirium and POCD, assessed from ICU admission until POD 7 and at 1 and 3 months postoperatively. This study was registered with the Chinese Clinical Trials Registry (ChiCTR1800020414).

RESULTS: Of 160 randomized participants, 155 were analyzed (77 gastrodin, 78 placebo) according to a modified intention to treat principle. The incidence of postoperative delirium was 19.5% in the gastrodin group and 35.9% in the placebo group, with a significant relative risk of 0.54 (95% CI 0.32-0.93, p = 0.022). The incidence of in-hospital POCD was 2.9% and 4.0% in the placebo and gastrodin groups, respectively. The odds of hospital discharge were significantly greater in the gastrodin group (subhazard ratio, 1.20; 95% CI 1.00-1.84; p = 0.049). Adverse events occurred in 9.1% (7/77) of patients administered gastrodin and 14.1% (11/78) of patients administered the placebo, with none being drug-related.

CONCLUSION: Gastrodin infusion significantly reduced postoperative delirium and improved discharge outcomes in patients undergoing CABG, but larger studies are needed to confirm its efficacy in preventing delirium.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Bai YX, Wu HL, Xie WL, et al. Efficacy and safety of gastrodin in preventing postoperative delirium following cardiac surgery: a randomized placebo controlled clinical trial. Crit Care. 2025. PMID: 40069830. doi:10.1186/s13054-025-05331-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。